Try our Advanced Search for more refined results

Pfizer Gets PTAB To Review Neulasta Patent In Amgen IP Row

By Britain Eakin (August 18, 2021, 4:28 PM EDT) -- The Patent Trial and Appeal Board has agreed to review an Amgen patent covering its blockbuster anti-infection drug Neulasta in a challenge brought by Pfizer and Hospira, rejecting Amgen's argument that the board should deny inter partes review based on the state of parallel litigation in Delaware....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!